Use of phy906 as treatment for inflammatory bowel disease and/or irritable bowel syndrome

Abstract

The present invention includes a method of using PHY906 for treating a bowel disorder including inflammatory bowel disease and irritable bowel syndrome. Particularly, the present invention provides a multiple symptoms treatment for the bowel disorder.

1 . A method of treating a bowel disorder comprising administering to a patient in need thereof a therapeutically effective amount of a composition comprising an herbal preparation having  Scutellaria, Glycyrrhiza, Ziziphus  and  Paeonia.    
     
     
         2 . The method of  claim 1 , which treat multiple symptoms of the bowel disorder. 
     
     
         3 . The method of  claim 2 , wherein the multiple symptoms comprises two or more symptoms selected from the group consisting of visceral pain, intestinal motility, inflammation, lower abdominal pain, bloating associated with alternation of bowel habits, abdominal discomfort relievable by defecation, fever, vomiting, acute diarrhea, positive stool culture, and combinations thereof. 
     
     
         4 . The method of  claim 1 , wherein the bowel disorder is inflammatory bowel disease (IBD) or irritable bowel syndrome (IBS). 
     
     
         5 . The method of  claim 4 , wherein the inflammatory bowel disease comprises a condition selected from the group consisting of Crohn's disease, ulcerative colitis (UC), collagenous colitis, lymphocytic colitis, ischaemic colitis, diversion colitis, Behçet's syndrome, infective colitis, indeterminate colitis, and combinations thereof. 
     
     
         6 . The method of  claim 4 , wherein the irritable bowel syndrome comprises a condition selected from the group consisting of diarrhea-predominant IBS, constipation-predominant IBS, alternating stool pattern IBS, post-infective IBS, and combinations thereof. 
     
     
         7 . The method of  claim 1 , further comprising co-administering to the patient in need thereof a therapeutically effective amount of at least one additional active agent. 
     
     
         8 . The method of  claim 7 , wherein the additional active agent is selected from the group consisting of an aminosalicylate, a corticosteroid, an immunomodulator, an antibiotic, a biologic, and combinations thereof. 
     
     
         9 . The method of  claim 7 , wherein the additional active agent is selected from the group consisting of a stool softener, a laxative, an antidiarrheal, an opiod or opiod analog, a tricyclic, a selective serotonin reuptake inhibitor, a probiotic, and combinations thereof. 
     
     
         10 . The method of  claim 1 , further comprising acupuncture or surgery. 
     
     
         11 . A method of inhibiting a δ-opioid receptor or a tachykinin NK-1 receptor by contacting the δ-opioid and tachykinin NK-1 receptors with a composition comprising an herbal preparation having  Scutellaria, Glycyrrhiza, Ziziphus  and  Paeonia.    
     
     
         12 . The method of  claim 11 , which comprises inhibiting both a δ-opioid receptor and a tachykinin NK-1 receptor. 
     
     
         13 . A method of treating a disease or condition associated with a disregulated δ-opioid receptor or tachykinin NK-1 receptor comprising administering to a patient in need thereof a therapeutically effective amount of a composition comprising an herbal preparation having  Scutellaria, Glycyrrhiza, Ziziphus  and  Paeonia.    
     
     
         14 . A method of inhibiting a nuclear factor-kappa B (NF-κB) by contacting the NF-κB with a composition comprising an herbal preparation having  Scutellaria, Glycyrrhiza, Ziziphus  and  Paeonia.    
     
     
         15 . The method of  claim 14 , wherein the NF-κB is an intrinsic or activated form of NF-κB. 
     
     
         16 . A method of treating a disease or condition associated with a disregulated NF-κB comprising administering to a patient in need thereof a therapeutically effective amount of a composition comprising an herbal preparation having  Scutellaria, Glycyrrhiza, Ziziphus  and  Paeonia.    
     
     
         17 . The method of  claim 1 , wherein the herbal preparation consists essentially of  Scutellaria, Glycyrrhiza, Ziziphus  and  Paeonia.    
     
     
         18 . The method of  claim 11 , wherein the herbal preparation consists essentially of  Scutellaria, Glycyrrhiza, Ziziphus  and  Paeonia.    
     
     
         19 . The method of  claim 13 , wherein the herbal preparation consists essentially of  Scutellaria, Glycyrrhiza, Ziziphus  and  Paeonia.    
     
     
         20 . The method of  claim 16 , wherein the herbal preparation consists essentially of  Scutellaria, Glycyrrhiza, Ziziphus  and  Paeonia.